查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2135407

依度沙班甲苯磺酸錠及非專利處方藥市場：全球市場預測，2026-2032年

Edoxaban Tosilate Tablets & Generic Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，依度沙班甲苯磺酸錠和學名藥市場將成長至 23.6 億美元，複合年成長率為 9.66%。

主要市場統計數據
基準年 2025 12.3億美元
預計年份：2026年 13.4億美元
預測年份 2032 23.6億美元
複合年成長率 (%) 9.66%

依度沙班甲苯磺酸錠及其學名藥：執行摘要

托西酸艾多沙班錠是一種口服抗凝血劑，用於降低符合臨床合格的患者（包括某些非瓣膜性心房顫動和靜脈血栓栓塞症患者）的血栓性栓塞症風險。法規核准、處方指南、保險報銷、生產品質、藥物安全監測以及品牌藥向學名藥的轉變等因素共同塑造了該藥的競爭格局和政策環境。本概述著重於實證的結構性趨勢，不提供市場估算、預測、佔有率或針對特定公司的說明。

學名藥的進入、證據要求和供應彈性正在重塑抗凝血劑的獲取途徑。

由於專利和獨佔權考量、學名藥核准途徑、治療等效性要求以及支付方為確保藥物可負擔性所做的努力等因素的相互作用，市場格局正在不斷演變。依度沙班的使用也取決於患者選擇、腎功能評估、劑量調整、藥物交互作用考量、對用藥依從性的支持。隨著供應商數量的增加，監管機構和採購方越來越重視活性成分品質的穩定性、檢驗的生產流程、供應的連續性、序列化以及有效的召回程序。臨床指導仍然至關重要，因為轉向學名藥並不能消除個體化抗凝血決策或定期重新評估出血和血栓風險的必要性。

在臨床監督下，人工智慧可以提高安全性、可預測性和營運管理水準。

人工智慧可以透過識別劑量差異、腎功能變化、禁忌症徵兆以及具有臨床意義的藥物交互作用，輔助電子健康記錄和藥房系統中的藥物安全篩檢。它還可以透過檢測不利事件報告中的訊號來支援藥物監測，幫助製造商識別生產過程中的偏差和文件缺陷。供應鏈應用包括需求預測、庫存優先排序、品管分析以及仿冒品和轉移產品的檢測。這些應用需要檢驗的模型、代表性的數據、網路安全措施、透明的管治以及手動審核。人工智慧應該輔助而非取代處方醫生和藥劑師的判斷。

北美、拉丁美洲、歐洲、中東和非洲以及亞太地區的情況各不相同。

在北美，成熟的監管體系與結構化的保險公司和藥房通路相結合較為普遍，處方藥清單、替代療法政策和上市後監測是影響藥品可及性的關鍵因素。在歐洲，統一的科學標準、國家衛生技術評估、採購和學名藥過渡備受重視，但各國的報銷和處方實踐各不相同。亞太地區擁有先進的藥品市場和快速發展的醫療保健系統，因此在藥品註冊、本地生產、分銷和可負擔性方面存在不同的要求。拉丁美洲的特徵是監管成熟度不一、公私合作採購模式各異，以及不同司法管轄區之間的藥品可近性差異。在中東，集中採購、進口限制和國家處方集決策會對藥品供應產生重大影響。非洲在診斷能力、抗凝血治療監測系統、採購資源和藥品供應連續性方面差異較大，凸顯了品質保證的分銷系統和臨床教育的重要性。

東協、金磚國家、歐盟、七國集團、海灣合作理事會和北約各自反映了不同的政策和採購重點。

東協市場在監管協調、對進口藥品原料的依賴以及公共部門採購結構方面存在差異。同時，金磚國家成員國擁有龐大且多元化的醫療保健系統，在藥品國內生產、報銷以及向學名藥轉型等方面採取了不同的方法。歐盟遵循通用的監管原則，但成員國在定價、報銷、採購和處方等方面仍有差異。七國集團（G7）的醫療保健系統普遍強調嚴格的品管、藥品安全監測和實證報銷，但藥品的可近性在很大程度上仍由各國自行決定。海灣合作理事會（GCC）國家通常採用集中採購和進口管制機制，因此更重視藥品供應的韌性和本地藥品生產能力。雖然北約並非醫療保健市場，但成員國之間的合作可能會提高對藥品供應連續性、緊急準備、網路安全和韌性醫療保健供應鏈的關注度。

各國具體優先事項包括監管替代方案、國內供應和臨床應用。

澳洲強調全國統一的報銷流程、療效等效性證據以及在地域分散的醫療保健系統中實現持續供應。巴西將聯邦法律規範與公共採購和私人分銷相結合，其中註冊、定價和可靠的供應至關重要。在加拿大，聯邦監管要求以及各省和地區的報銷決策共同影響著藥品的可及性。中國持續在監管現代化、集中採購、國內生產能力和品質保證之間尋求平衡。法國、德國、義大利和西班牙在歐洲框架內運作，同時實施各自的國家報銷、採購、處方和替代政策。印度擁有強大的學名藥生產能力，但需要格外關注監管合規性、品質一致性和廣泛分銷。日本在其國內報銷體系中高度重視監管審查、藥品安全監測和合理用藥。墨西哥的藥品可近性環境體現了聯邦監管、公共採購和私部門通路。俄羅斯的藥品政策將穩定國內生產和供應作為優先事項，而這必須符合國家監管要求。韓國將嚴格的法律規範與國家健保報銷和技術採納流程結合。在英國，上市後監測、國家臨床指南以及涵蓋各種醫療保健計劃的個人醫保報銷系統都已到位。美國則受聯邦核准要求、保險公司處方藥清單、藥房福利結構、替代處方法以及廣泛的藥物安全監測義務的影響。

產業領導者應優先考慮相容性證據、品管系統和病人安全基礎設施。

領導者應制定針對特定市場的監管合規計劃，涵蓋生物等效性或治療等效性的證據、標籤、劑量和濃度要求、生產許可和替代規則。他們也應加強關鍵原料和成品的雙重採購、檢驗的供應商合格、可追溯性、序列化和緊急儲備。銷售和醫療團隊應透過提供清晰的訊息，支持合理用藥，包括腎功能評估、藥物交互作用篩檢、用藥依從性教育和出血風險預防措施。藥物安全監測系統應在可接受的範圍內整合自發性報告、保險索賠數據和臨床數據，並能夠快速評估訊號。實施人工智慧的機構應嚴格界定其範圍，從可審計的用例入手，並建立檢驗、偏差測試、存取控制、模型監測和臨床醫生課責的管治。

調查方法：對監管、臨床、供應鏈和國家層面的證據進行三角檢驗。

本執行摘要使用提供的市場定義（依度沙班托西酸鹽片和學名藥），透過對公開的監管原則、臨床應用考慮、學名藥要求、報銷和採購機制、藥物安全監測實踐以及區域醫療保健系統特徵進行結構化審查，來組織研究結果。本分析區分了檢驗的結構性發現和無根據的商業性假設，不包括市場估算和預測、市場規模、市場佔有率、預測以及公司特定聲明。區域、群體和國家的具體說明相對定性，在做出實際決策時，應補充最新的監管公告、處方集、治療指南、採購文件以及各司法管轄區特有的安全資訊。

可靠的存取取決於品質、正確使用和強大的分發能力。

依度沙班甲苯磺酸錠及其學名藥的地位並非由單一商業性因素決定，而是由一系列要求綜合考量，包括臨床有效性、法規遵從性、生產品質、醫保報銷、供應連續性和上市後安全性。儘管實施條件因地區和國家而異，但抗菌藥物（AI）只有在精心管理下才能有效發揮作用，並保障藥物安全。永續發展需要循證的替代處方、健全的品管系統、負責任的病人支持、透明的監管以及對安全性和供應狀況的持續監測。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：依度沙班甲苯磺酸片及非專利處方藥市場：依藥物類型分類

  • 品牌名稱產品：艾多沙班托西酸鹽
    • 領先品牌
    • 已經過核准品牌產品
  • 艾多沙班甲苯磺酸鹽非專利處方藥
    • 已通過核准的學名藥
    • 標準學名藥
    • 超級非專利藥品藥

第8章：依度沙班甲苯磺酸片及非專利處方藥市場：依治療應用分類

  • 預防深層靜脈栓塞症（DVT）復發
  • 心房顫動患者中風預防
  • 深層靜脈栓塞症和肺動脈栓塞的治療

第9章：依度沙班甲苯磺酸片及非專利處方藥市場：依劑量強度分類

  • 15 mg
  • 30 mg

第10章：依度沙班甲苯磺酸錠及非專利處方藥市場：依分銷通路分類

  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
    • 製造商門戶
    • 藥局入口網站
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第11章：依度沙班甲苯磺酸片及非專利處方藥市場：依最終用戶分類

  • 診所
    • 門診部
    • 專科診所
  • 家庭醫療保健
    • 行政支援
    • 自我管理
  • 醫院
    • 醫院病房
    • 門診治療

第12章：依度沙班甲苯磺酸片及非專利處方藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：依度沙班甲苯磺酸錠及非專利處方藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：依度沙班甲苯磺酸片及非專利處方藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Aurobindo Pharma Limited
  • Cipla Limited
  • CTX Lifesciences
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Limited
  • Hikal Limited
  • Honour Lab Limited
  • Lupin Limited
  • Menarini Group
  • Metrochem API Private Limited
  • MSN Life Sciences
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Taj Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zhejiang Tianyu Pharmaceutical Co., Ltd.
  • Zydus Lifesciences Ltd.

第17章 主要專家

Product Code: MRR-961F26FD6413

The Edoxaban Tosilate Tablets & Generic Drugs Market is projected to grow by USD 2.36 billion at a CAGR of 9.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.23 billion
Estimated Year [2026] USD 1.34 billion
Forecast Year [2032] USD 2.36 billion
CAGR (%) 9.66%

Edoxaban Tosilate Tablets and Generic Drugs: Executive Summary

Edoxaban tosylate tablets are oral anticoagulant medicines used to reduce thromboembolic risk in clinically appropriate patients, including certain individuals with non-valvular atrial fibrillation and venous thromboembolism. The competitive and policy environment is shaped by regulatory approval, prescribing guidance, reimbursement, manufacturing quality, pharmacovigilance, and the transition from originator products to generic alternatives. This summary focuses on evidence-based structural developments without providing market estimates, forecasts, shares, or company-specific commentary.

Generic Entry, Evidence Requirements, and Supply Resilience Are Reshaping Anticoagulant Access

The landscape is being transformed by the interaction of patent and exclusivity considerations, generic-drug approval pathways, therapeutic-equivalence requirements, and payer efforts to improve affordability. Edoxaban use also depends on patient selection, renal-function assessment, dose adjustment, drug-interaction review, and adherence support. As more suppliers participate, regulators and purchasers place greater emphasis on consistent active-pharmaceutical-ingredient quality, validated manufacturing processes, continuity of supply, serialization, and effective recall procedures. Clinical guidance remains central because generic substitution does not remove the need for individualized anticoagulation decisions or periodic reassessment of bleeding and thrombotic risk.

Artificial Intelligence Can Improve Safety, Forecasting, and Operational Control-With Clinical Oversight

Artificial intelligence can support medication-safety screening by identifying potential dose mismatches, renal-function changes, contraindication signals, and clinically important drug interactions in electronic health records and pharmacy systems. It can also assist pharmacovigilance through signal detection across adverse-event reports and help manufacturers identify process deviations or documentation anomalies. Supply-chain applications include demand sensing, inventory prioritization, quality-control analytics, and detection of counterfeit or diverted products. These uses require validated models, representative data, cybersecurity controls, transparent governance, and human review; AI should support rather than replace prescriber and pharmacist judgment.

Regional Conditions Differ Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America generally combines mature regulatory systems with structured payer and pharmacy channels, making formulary positioning, therapeutic interchange policies, and post-market surveillance important access factors. Europe places strong emphasis on centralized scientific standards, national health-technology assessment, procurement, and generic substitution, although reimbursement and prescribing practices differ across countries. Asia-Pacific includes advanced pharmaceutical markets alongside rapidly expanding healthcare systems, creating varied requirements for registration, local manufacturing, distribution, and affordability. Latin America is characterized by diverse regulatory maturity, public-private purchasing models, and uneven access across jurisdictions. In the Middle East, centralized procurement, import controls, and national formulary decisions can strongly influence availability. Africa faces greater variation in diagnostic capacity, anticoagulation monitoring infrastructure, procurement resources, and medicine-supply continuity, increasing the importance of quality-assured distribution and clinical education.

ASEAN, BRICS, the European Union, G7, GCC, and NATO Reflect Distinct Policy and Procurement Priorities

ASEAN markets differ in regulatory harmonization, dependence on imported pharmaceutical inputs, and public-sector procurement structures, while BRICS members span large and diverse healthcare systems with differing approaches to domestic production, reimbursement, and generic substitution. The European Union operates through shared regulatory principles but retains national differences in pricing, reimbursement, procurement, and prescribing. G7 systems generally emphasize stringent quality oversight, pharmacovigilance, and evidence-based reimbursement, although access pathways remain nationally determined. GCC countries often use centralized purchasing and import-regulatory mechanisms, with growing attention to supply resilience and local pharmaceutical capability. NATO is not a healthcare market, but its member-state cooperation can elevate interest in pharmaceutical continuity, emergency preparedness, cybersecurity, and resilient medical supply chains.

Country-Level Priorities Range From Regulatory Substitution Rules to Domestic Supply and Clinical Adoption

Australia emphasizes national reimbursement processes, therapeutic-equivalence evidence, and supply continuity across a geographically dispersed healthcare system. Brazil combines federal regulatory oversight with public procurement and private distribution, making registration, pricing, and dependable supply important. Canada's provincial and territorial reimbursement decisions influence access alongside federal regulatory requirements. China continues to balance regulatory modernization, centralized purchasing, domestic manufacturing capability, and quality assurance. France, Germany, Italy, and Spain operate within the European framework while applying distinct national reimbursement, procurement, prescribing, and substitution policies. India has substantial generic-manufacturing capacity but requires careful attention to regulatory compliance, quality consistency, and broad distribution. Japan places strong emphasis on regulatory review, pharmacovigilance, and appropriate use within its national reimbursement system. Mexico's access environment reflects federal regulation, public procurement, and private-sector channels. Russia's pharmaceutical policy includes domestic-production and supply-security priorities subject to national regulatory requirements. South Korea combines rigorous regulatory oversight with national reimbursement and technology-adoption processes. The United Kingdom applies post-market monitoring, national clinical guidance, and separate reimbursement arrangements across its health systems. The United States is shaped by federal approval requirements, payer formularies, pharmacy-benefit structures, substitution laws, and extensive pharmacovigilance obligations.

Industry Leaders Should Prioritize Interchangeability Evidence, Quality Systems, and Patient-Safety Infrastructure

Leaders should maintain a market-by-market regulatory plan covering bioequivalence or therapeutic-equivalence evidence, labeling, dose-strength requirements, manufacturing authorization, and substitution rules. They should strengthen dual sourcing, validated supplier qualification, traceability, serialization, and contingency inventories for critical materials and finished products. Commercial and medical teams should support appropriate use through renal-function assessment, interaction screening, adherence education, and clear communication about bleeding-risk precautions. Pharmacovigilance systems should integrate spontaneous reports, claims or clinical data where permitted, and rapid signal evaluation. Organizations adopting AI should begin with narrowly defined, auditable use cases and establish governance for validation, bias testing, access controls, model monitoring, and clinician accountability.

Methodology: Triangulating Regulatory, Clinical, Supply-Chain, and Country-Level Evidence

This executive summary uses the supplied market definition-edoxaban tosylate tablets and generic drugs-and organizes findings through a structured review of publicly available regulatory principles, clinical-use considerations, generic-medicine requirements, reimbursement and procurement mechanisms, pharmacovigilance practices, and regional healthcare-system characteristics. The analysis distinguishes verified structural insights from unsupported commercial assumptions and excludes market estimates, market sizing, market shares, forecasts, and company-specific claims. Regional, group, and country narratives are comparative and qualitative; they should be supplemented with current jurisdiction-specific regulatory notices, formularies, treatment guidelines, procurement documents, and safety communications before operational decisions are made.

Reliable Access Depends on Quality, Appropriate Use, and Resilient Distribution

The edoxaban tosylate tablet and generic-drug landscape is defined less by a single commercial variable than by the combined requirements of clinical appropriateness, regulatory compliance, manufacturing quality, reimbursement access, supply continuity, and post-market safety. Regional and country differences create distinct implementation conditions, while AI offers useful operational and pharmacovigilance capabilities only when governed carefully. Durable progress will depend on evidence-based substitution, robust quality systems, responsible patient support, transparent oversight, and continuous monitoring of safety and availability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Edoxaban Tosilate Tablets & Generic Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Branded Edoxaban Tosilate
    • 7.2.1. Originator Brand
    • 7.2.2. Licensed Brand
  • 7.3. Generic Edoxaban Tosilate
    • 7.3.1. Authorized Generic
    • 7.3.2. Standard Generic
    • 7.3.3. Super Generic Formulations

8. Edoxaban Tosilate Tablets & Generic Drugs Market, by Therapeutic Application

  • 8.1. Introduction
  • 8.2. Prevention Of Recurrence Of Dvt Pe
  • 8.3. Stroke Prevention In Atrial Fibrillation
  • 8.4. Treatment Of Deep Vein Thrombosis And Pulmonary Embolism

9. Edoxaban Tosilate Tablets & Generic Drugs Market, by Dosage Strength

  • 9.1. Introduction
  • 9.2. 15 Mg
  • 9.3. 30 Mg

10. Edoxaban Tosilate Tablets & Generic Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
    • 10.2.1. Private Hospital
    • 10.2.2. Public Hospital
  • 10.3. Online Pharmacy
    • 10.3.1. Manufacturer Portal
    • 10.3.2. Pharmacy Portal
  • 10.4. Retail Pharmacy
    • 10.4.1. Chain Pharmacy
    • 10.4.2. Independent Pharmacy

11. Edoxaban Tosilate Tablets & Generic Drugs Market, by End User

  • 11.1. Introduction
  • 11.2. Clinic
    • 11.2.1. Outpatient Clinic
    • 11.2.2. Specialty Clinic
  • 11.3. Home Healthcare
    • 11.3.1. Assisted Administration
    • 11.3.2. Self Administration
  • 11.4. Hospital
    • 11.4.1. Inpatient Department
    • 11.4.2. Outpatient Department

12. Edoxaban Tosilate Tablets & Generic Drugs Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Edoxaban Tosilate Tablets & Generic Drugs Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Edoxaban Tosilate Tablets & Generic Drugs Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Aurobindo Pharma Limited
  • 16.2. Cipla Limited
  • 16.3. CTX Lifesciences
  • 16.4. Daiichi Sankyo Co., Ltd.
  • 16.5. Dr. Reddy's Laboratories Limited
  • 16.6. Hikal Limited
  • 16.7. Honour Lab Limited
  • 16.8. Lupin Limited
  • 16.9. Menarini Group
  • 16.10. Metrochem API Private Limited
  • 16.11. MSN Life Sciences
  • 16.12. Sandoz International GmbH
  • 16.13. Sun Pharmaceutical Industries Limited
  • 16.14. Taj Pharma
  • 16.15. Teva Pharmaceutical Industries Ltd.
  • 16.16. Viatris Inc.
  • 16.17. Zhejiang Tianyu Pharmaceutical Co., Ltd.
  • 16.18. Zydus Lifesciences Ltd.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Edoxaban Tosilate Tablets & Generic Drugs Market, Years Considered for the Study
  • FIGURE 2. Global Edoxaban Tosilate Tablets & Generic Drugs Market, Research Design
  • FIGURE 3. Global Edoxaban Tosilate Tablets & Generic Drugs Market, Research Framework
  • FIGURE 4. Global Edoxaban Tosilate Tablets & Generic Drugs Market, Data Triangulation
  • FIGURE 5. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2025 vs 2032 (%)
  • FIGURE 9. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2025 vs 2032 (%)
  • FIGURE 11. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Edoxaban Tosilate Tablets & Generic Drugs Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Edoxaban Tosilate Tablets & Generic Drugs Market Segmentation & Coverage
  • TABLE 2. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 4. Global Branded Edoxaban Tosilate Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Branded Edoxaban Tosilate Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Branded Edoxaban Tosilate Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Originator Brand Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Originator Brand Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Originator Brand Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Licensed Brand Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Licensed Brand Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Licensed Brand Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Generic Edoxaban Tosilate Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Generic Edoxaban Tosilate Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Generic Edoxaban Tosilate Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Authorized Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Authorized Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Authorized Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Standard Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Standard Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Standard Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Super Generic Formulations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Super Generic Formulations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Super Generic Formulations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 26. Global Prevention Of Recurrence Of Dvt Pe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Prevention Of Recurrence Of Dvt Pe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Prevention Of Recurrence Of Dvt Pe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Stroke Prevention In Atrial Fibrillation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Stroke Prevention In Atrial Fibrillation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Stroke Prevention In Atrial Fibrillation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Treatment Of Deep Vein Thrombosis And Pulmonary Embolism Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Treatment Of Deep Vein Thrombosis And Pulmonary Embolism Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Treatment Of Deep Vein Thrombosis And Pulmonary Embolism Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 36. Global 15 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global 15 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global 15 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global 30 Mg Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global 30 Mg Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global 30 Mg Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 43. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Private Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Private Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Private Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Public Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Public Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Public Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global Manufacturer Portal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Manufacturer Portal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Manufacturer Portal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Pharmacy Portal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Pharmacy Portal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Pharmacy Portal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Chain Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Chain Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Chain Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Independent Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Independent Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Independent Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 71. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Outpatient Clinic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global Outpatient Clinic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global Outpatient Clinic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Assisted Administration Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Assisted Administration Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Assisted Administration Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Self Administration Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Self Administration Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Self Administration Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 92. Global Inpatient Department Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Global Inpatient Department Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. Global Inpatient Department Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 95. Global Outpatient Department Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Global Outpatient Department Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. Global Outpatient Department Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 98. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 101. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 102. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 103. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 104. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 105. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 106. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 107. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 108. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 109. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 110. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 111. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 112. Asia-Pacific Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 113. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 115. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 116. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 117. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 118. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 119. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 120. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 121. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 122. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 123. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 124. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 125. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 126. North America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 127. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 128. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 129. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 130. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 131. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 132. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 133. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 134. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 135. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 136. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 137. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 138. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 139. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 140. Latin America Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 141. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 142. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 143. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 144. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 145. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 146. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 147. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 148. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 149. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 150. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 151. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 152. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 153. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 154. Europe Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 155. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 156. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 157. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 158. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 159. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 160. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 161. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 162. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 163. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 164. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 165. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 166. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 167. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 168. Middle East Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 169. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 170. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 171. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 172. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 173. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 174. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 175. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 176. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 177. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 178. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 179. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 180. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 181. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 182. Africa Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 183. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 184. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 185. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 186. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 187. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 188. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 189. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 190. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 191. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 192. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 193. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 194. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 195. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 196. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 197. ASEAN Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 198. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 199. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 200. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 201. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 202. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 203. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 204. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 205. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 206. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 207. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 208. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 209. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 210. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 211. GCC Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 212. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 213. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 214. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 215. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 216. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 217. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 218. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 219. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 220. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 221. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 222. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 223. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 224. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 225. European Union Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 226. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 227. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 228. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 229. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 230. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 231. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 232. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 233. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 234. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 235. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 236. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 237. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 238. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 239. BRICS Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 240. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 241. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 242. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 243. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 244. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 245. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 246. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 247. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 248. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 249. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 250. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 251. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 252. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 253. G7 Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 254. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 255. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 256. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 257. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 258. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 259. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 260. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 261. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 262. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 263. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 264. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 265. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 266. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 267. NATO Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 268. Global Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 269. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 270. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 271. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 272. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 273. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 274. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 275. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 276. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 277. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 278. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 279. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 280. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 281. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 282. United States Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 283. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 284. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 285. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 286. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 287. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 288. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 289. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 290. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 291. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Online Pharmacy, 2017-2032 (USD Million)
  • TABLE 292. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
  • TABLE 293. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 294. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Clinic, 2017-2032 (USD Million)
  • TABLE 295. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Home Healthcare, 2017-2032 (USD Million)
  • TABLE 296. Canada Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Hospital, 2017-2032 (USD Million)
  • TABLE 297. Mexico Edoxaban Tosilate Tablets & Generic Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 298. Mexico Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 299. Mexico Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Branded Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 300. Mexico Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Generic Edoxaban Tosilate, 2017-2032 (USD Million)
  • TABLE 301. Mexico Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Therapeutic Application, 2017-2032 (USD Million)
  • TABLE 302. Mexico Edoxaban Tosilate Tablets & Generic Drugs Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 303. Mexico Edoxaban Tosilate Tablets & Generic Drugs M